On responders, this is the rare cosmetic drug that does what the bottle claims — visible density change by month six, sustained for as long as you keep applying it. Generic 5% costs about ten dollars a month. The catch is the cadence: stop using it for a season and the hair you grew back is gone, plus the loss that was happening quietly underneath. Sign up only if you're willing to commit for years.
How it actually works
Minoxidil is a prodrug — what you rub on your scalp is inert. An enzyme in your hair follicles called sulfotransferase converts it into its active form, minoxidil sulfate. That active form opens potassium channels on the cells at the base of each follicle, which (through a chain of downstream effects) extends the growth phase of the hair cycle and shortens the resting phase. Follicles that were on their way to dying instead get another run.
The catch shows up in two places. First, sulfotransferase activity varies roughly ten-fold between people; one person's follicles convert the drug efficiently and another's barely convert it at all. This is most of why response rates land around four in ten and not nine in ten (Shorter et al. 2008). Second — and the part most users miss — minoxidil does not block the hormone (called DHT) that drives pattern hair loss in the first place. It works downstream. The underlying clock is still ticking; you're holding it back from the other end.
Does it actually work
About four in ten users see clear regrowth by six months. Another three in ten hold what they have. The remaining three see nothing — usually because their follicles can't activate the drug. These numbers are remarkably stable across decades of trials.
You won't see anything before the three-month mark. Visible density change typically lands between months four and six, peaks around month twelve, and then enters a maintenance phase: you keep applying, you keep what you grew. Photo-on-photo comparison at six and twelve months is the standard way clinicians track response — by feel alone, it's hard to notice a gradual change in your own scalp.
The oral version performs comparably to the topical. A 2025 meta-analysis of four head-to-head trials found no significant difference in hair density between 1–5 mg daily oral and 5% twice-daily topical (Sobral et al. 2025). The largest multicenter safety series — 1,404 patients on a mean dose of 1.6 mg/day — reported under 2% discontinuation across the follow-up window (Vañó-Galván et al. 2021). The trade-off: oral works systemically, so unwanted hair shows up on your cheeks, forearms, and ears more often than with topical.
How to use it
The standard topical protocol is the 5% formulation, applied to a dry scalp twice a day, covering the thinning areas. A 1 mL solution dose looks like a small puddle in your palm; a foam dose is roughly half a capful. Massage in with fingertips and let it dry for two or three minutes before doing anything with your hair. Morning and night.
If propylene glycol — the carrier in the liquid — irritates your scalp, switch to the foam. The active ingredient and concentration are identical; only the vehicle differs (Friedman et al. 2002). Women have an FDA-approved once-daily 5% foam protocol with results non-inferior to twice-daily 2% solution; men can use the same approach off-label, but cutting down to once-daily at the same strength measurably costs density over time.
Low-dose oral is twice-daily-out, single-pill-in. Standard starting doses are 0.625 mg/day for women and 2.5 mg/day for men, escalated every three months toward a ceiling of 2.5 mg (women) or 5 mg (men) (Gupta et al. 2024). Resting heart rate gets checked before and during titration; a jump of 20 beats per minute calls for a dose reduction. Generic 5% topical foam runs $10–15 a month; the compounded oral runs $30–60 in the US, far less from European generic markets.
When not to use it
Don't use topical or oral minoxidil if you're pregnant or breastfeeding. The drug crosses into breast milk; there's a documented case of a nursing infant developing thick black hair on the forehead while the mother used 5% topical. It isn't a known teratogen, but the data isn't strong enough to call it safe either. Most clinicians ask women trying to conceive to taper off before they start trying.
Low-dose oral is broadly well-tolerated in healthy adults, but it does mildly raise heart rate and can cause fluid retention. If you have known coronary artery disease, an untreated arrhythmia, or significant kidney impairment, this isn't the version for you — stay on topical. The very rare cases of pericardial effusion (fluid around the heart) at low-dose oral have nearly all traced back to compounding errors: in one cohort, a patient's prescription contained 1,000 mg per tablet instead of 1 mg (Randolph & Tosti 2021). Buy from a regulated pharmacy.
The dread shed, and other things people get wrong
For the first four to eight weeks, many users see more hair coming out, not less. The internet calls this the "dread shed" and treats it as a sign the drug is failing. It's the opposite. Minoxidil works partly by synchronising follicles — hairs that were already in line to fall out in the coming months all get released at once and immediately re-enter the growth phase. The drawer-full-of-hair month is the drug doing what it does. Most users who quit minoxidil quit here.
Two other things people get wrong. First: the foam is not weaker than the solution. The active ingredient and concentration are identical; only the carrier is different. The foam exists because the liquid's propylene glycol irritates roughly one in fifteen scalps (Friedman et al. 2002). Second: when people stop minoxidil and lose the hair they grew, it can feel like the drug "caused" the loss. It didn't. Pattern hair loss was progressing the whole time underneath, masked by the regrowth. Stopping just reveals the underlying trajectory in fast-forward — the hair was never going to stay free.
Why it doesn't work for everyone
The largest single reason is the enzyme that activates the drug. Sulfotransferase activity in the scalp varies roughly ten-fold between people. A 2014 study showed that a follicular enzyme test predicted non-responders with 95% sensitivity — meaning if you have low activity, the topical is unlikely to ever do much for you (Goren et al. 2014). The fix: switch to oral (which is activated systemically rather than in the follicle), or pair the topical with weekly microneedling, which raises local enzyme activity (Dhurat & Ogeti 2017).
The other common failures are adherence (twice a day, every day, for at least four months before you can judge) and starting too late. A scalp that's been losing hair for fifteen years has fewer follicles left to recruit; minoxidil only works on follicles still capable of producing hair. Daily aspirin also blunts the topical's effect — same enzyme-inhibition story (Goren et al. 2014).
Beards, women, and people on testosterone
Off-label, minoxidil grows facial hair the same way it grows scalp hair — anagen extension on follicles that already have the wiring. A 2016 Thai trial gave 48 men with patchy beards 3% topical twice daily and measured a statistically significant hair-count increase at 16 weeks (Ingprasert et al. 2016). A 2024 placebo-controlled trial in transgender men on stable testosterone reported large effects at 12 weeks: +11.16 beard hairs/cm² and +18.45 mustache hairs/cm² over placebo (Panchaprateep et al. 2024). What hasn't been tested: whether the gains persist after you stop applying it. Best guess from small case series — coarse terminal hairs may stay, vellus hairs probably don't.
For women with pattern hair loss, the FDA-approved formulation is 5% foam once daily (Bergfeld et al. 2016). Response rates resemble men's, but the absolute density gain is smaller because the underlying loss is diffuse rather than focal. Low-dose oral works the same as in men with conservative dose ceilings (2.5 mg/day) and higher attention to facial hypertrichosis — fine upper-lip or sideburn hairs are the most common reason women drop the oral version (Sinclair 2018).
What untreated pattern hair loss looks like over a decade
Roughly half of men have visible loss by 50, four in five by 70. Around four in ten women have it by 70 too — usually as a widening part rather than a receding hairline. Untreated, the trajectory is steady and one-directional. The crown thins year over year; the temples retreat. By month, nothing changes; by decade, the photograph you took in your twenties looks like a different person.
The biological stakes are zero. Pattern hair loss isn't bad for your body. The social stakes are what they are: hair loss is associated with measurable decrements in self-perceived attractiveness, modest self-esteem effects, and small increases in depressive symptoms in cross-sectional data — bigger in women, where the pattern reads as illness in a way the male pattern doesn't. None of this is dramatic on its own. It's the cumulative weight over years of mirrors and photographs that does the work.
What changes if you start, week by year
Weeks 2 to 8. More hair in the drain. This is the dread shed. The instinct is to quit; the right move is to wait.
Months 3 to 4. The shed stops. Fine, downy regrowth shows up in your temples or on the crown — visible if you look hard, easy to miss day to day.
Months 6 to 12. On responders, photo-on-photo comparison shows clear density change. The people who haven't seen you in a while comment that something looks different. This is the peak effect.
Years 1 to 5+. Maintenance phase. The hair you grew stays, conditional on continued application. The untreated counterfactual — the version of you who didn't start — keeps losing density. The gap between the two grows every year.
The catch is the same one the opening named. Stop the drug at year five and the hair you grew is gone within six months, plus the five years of loss that were happening underneath. The 1987 discontinuation study made this stark: in ten men taken off minoxidil after months of regrowth, hair counts had returned to baseline within three months, and four of ten dropped below baseline (Olsen et al. 1987).
What pairs with minoxidil
Minoxidil works downstream of the hormone that drives pattern hair loss. To attack the loss from both ends, pair it with a 5α-reductase inhibitor — oral or topical finasteride for most users, dutasteride for those who don't respond to finasteride. Microneedling once a week raises local response and is a free intervention if you already own a dermaroller. Ketoconazole shampoo has weak but non-zero evidence as a small adjunct. Past medication, the only intervention that actually grows new follicles where none remain is hair transplant.
- — If minoxidil regrowth has stalled, weekly scalp microneedling can multiply its effect — it's built to be paired with it.
- — Finasteride attacks pattern baldness from the hormone side; minoxidil works on the follicle — many people run both.
- — A transplant moves permanent follicles; minoxidil is the daily, non-surgical route — and most patients keep using it even after surgery.
- — Adding microneedling to minoxidil markedly boosts regrowth versus the drug alone.
- — If minoxidil has stalled, red-light caps and panels are an evidence-backed add-on for early thinning.
- — Minoxidil is a first-line hair treatment; saw palmetto is a much weaker option people reach for instead.
Substance and claimed effects
Minoxidil is a piperidinopyrimidine vasodilator originally developed for severe hypertension and approved orally by the FDA in 1979 as Loniten. Hypertrichosis was a near-universal side effect at antihypertensive doses (10–40 mg/day), which led to topical reformulation; Upjohn's 2% solution was approved as Rogaine for male androgenetic alopecia (AGA) in 1988 (FDA 1988) and for female pattern hair loss (FPHL) in 1991. The 5% solution followed in the late 1990s, the propylene-glycol-free foam in the mid-2000s, and low-dose oral minoxidil (LDOM, 0.25–5 mg/day) emerged as a widely-used off-label option in the 2010s, popularised by Sinclair's group in Australia (Sinclair 2018) and a 2022 New York Times article that produced a documented prescribing surge (Kolata 2022).
This entry covers: (1) topical minoxidil 2% and 5% (solution and foam) for scalp AGA in men and women; (2) low-dose oral minoxidil 0.25–5 mg/day for the same indication; (3) topical minoxidil for facial-hair enhancement (beard, moustache, eyebrow) in men and in t-AFAB individuals on gender-affirming hormone therapy. Consequences scored: a real direct cosmetic effect on hair density visible within 3–6 months on responders (~40% of users), a cumulative aesthetic benefit over years of continued use, a small indirect mood effect mediated by appearance change, and modest effort + cost burden offset by very strong evidence and low controversy.
Evidence by addressing question
Mechanism
Minoxidil is a prodrug. Conversion to its active metabolite, minoxidil sulfate, depends on the enzyme sulfotransferase SULT1A1 expressed in the outer root sheath of hair follicles. Inter-individual SULT1A1 activity varies roughly 10-fold and tracks closely with clinical response (Goren 2014); a follicular sulfotransferase assay rules out 95.9% of non-responders to topical minoxidil with 95% sensitivity and 73% specificity. Aspirin inhibits SULT1A1 — in one cohort, 14 days of oral aspirin reduced the predicted-responder fraction from 50% to 27%.
Minoxidil sulfate then opens ATP-sensitive K+ channels (KATP) on the dermal papilla cell membrane. Shorter et al. mapped the receptor in human follicles: dermal papilla and dermal sheath express the SUR2B/Kir6.1 channel that minoxidil specifically activates; epithelial matrix expresses SUR1/Kir6.2, which does not respond to minoxidil (Shorter 2008). KATP opening hyperpolarises the membrane, which downstream is associated with prolongation of anagen, shortening of telogen, and reversal of miniaturisation in genetically susceptible follicles.
Several adjunct mechanisms are documented but contribute to a less-clean story: minoxidil up-regulates VEGF, PGE2 (via COX-1), and nitric oxide production in follicular fibroblasts, and increases intracellular Ca2+ in dermal papilla cells. The KATP-channel story remains the consensus primary mechanism, though SUR2B-targeting compounds have not yet outperformed minoxidil in clinical trials. Importantly, minoxidil does not block dihydrotestosterone (DHT), the upstream driver of AGA — it acts entirely downstream of the androgen signal, which is why long-term continuation is required and why combining it with a 5α-reductase inhibitor (finasteride, dutasteride) is synergistic (Suchonwanit 2018).
Evidence
Topical minoxidil has one of the densest evidence bases of any over-the-counter intervention in dermatology. The pivotal 48-week, 393-man RCT by Olsen et al. established the 5% solution as superior to 2% (45% more regrowth) and to placebo (mean +18.6 non-vellus hairs/cm² vs +3.9, six of six efficacy endpoints) (Olsen et al. 2002). For women, the 5% foam pivotal trial (n=404) showed +10.9 hairs/cm² over vehicle at 24 weeks (Bergfeld 2016). A 2023 Bayesian network meta-analysis of 17 RCTs places topical minoxidil 5% as the most effective FDA-approved topical monotherapy for male AGA; oral finasteride 1 mg ranks as the most effective oral monotherapy, dutasteride 0.5 mg as the most effective overall.
LDOM has accumulated rapid RCT support. A 2025 meta-analysis of four head-to-head RCTs (n=279) found no significant difference in hair density or diameter between LDOM 1–5 mg/day and topical minoxidil 5% (SMD 0.02, 95% CI −0.25 to 0.29) — but hypertrichosis was significantly more common with oral (Sobral 2025). Asilian's 2024 RCT (65 patients, 6 months) reported topical numerically superior but not significantly different from 1 mg oral. A 12-month retrospective of 502 men on finasteride 1 mg + minoxidil 2.5 mg oral combination reported 92.4% stable-or-improved and 57.4% overt regrowth.
For beard enhancement, the evidence is thinner but consistent. Ingprasert's 16-week double-blind RCT (n=48 Thai men) showed significant hair-count increases with 3% topical minoxidil (Ingprasert 2016). The 2025 Panchaprateep RCT in 69 transgender men on stable testosterone reported +11.16 hairs/cm² beard density vs +0.08 placebo (p=0.01) and +18.45 mustache vs +1.74 (p=0.003) at 12 weeks (Panchaprateep 2024). Mechanism aligns: the androgen-receptor density on facial follicles is high in genetically responsive individuals, and minoxidil-induced anagen prolongation translates to thicker, longer terminal hairs in this body region.
Limitations of the literature: most trials are 24–48 weeks (insufficient for the long-tail response-attenuation question raised by Price's 96-week trial, in which efficacy began to wane after week 12); FPHL trials are smaller than male AGA trials; head-to-head topical-vs-oral data is still <500 patients pooled. Discontinuation evidence is unambiguous — Olsen 1987 reported that scalp-hair counts returned to or below baseline within 3 months of stopping minoxidil (Olsen 1987); Price 1999 replicated this through week 120.
Protocol
Topical. 5% solution 1 mL twice daily, or 5% foam half-capful (a fingertip's worth) twice daily, applied to a dry scalp covering thinning areas. Solution penetrates slightly better but contains propylene glycol; foam is propylene-glycol-free and lower in irritation (Friedman 2002). For women, the FDA-approved formulation is 5% foam once daily, supported by Phase III non-inferiority data against 2% solution twice daily; the same once-daily 5% strategy is increasingly used off-label in men.
Oral (off-label). Sinclair's dosing convention: women start at 0.625 mg/day, escalate every 3 months to a typical 1.25–2.5 mg ceiling; men start at 2.5 mg/day, escalate to 5 mg/day; rare cases titrate to 7.5–10 mg under cardiology supervision (Gupta 2024). Resting heart rate is monitored before and after dose changes; an increase of ≥20 bpm prompts dose reduction. The Vañó-Galván 1404-patient multicenter safety series (mean dose 1.63 mg/day) reported <2% discontinuation (Vañó-Galván 2021).
Facial hair. 3–5% topical once or twice daily, applied to dry facial skin in target areas. Trials run 12–24 weeks; clinical experience suggests longer plateaus around 6–12 months. Persistence after discontinuation is the open question — small case series suggest terminal hairs may persist while vellus hairs regress, but no controlled data exists.
Adjuncts. Microneedling (1.5 mm, weekly) potentiates topical minoxidil response in non-responders (Dhurat 2017); topical 0.25% finasteride co-formulated with 3% minoxidil outperforms minoxidil monotherapy on hair density, diameter, and global photographic assessment with minimal systemic DHT change (Suchonwanit 2018). The standard "Big 3" stack for male AGA is finasteride + minoxidil + ketoconazole shampoo.
Contraindications
Topical: pregnancy and breastfeeding (case reports of neonatal hypertrichosis from maternal use, drug excreted in breast milk; not a documented teratogen but causal data inadequate), active scalp dermatitis, hypersensitivity to minoxidil itself (rare) or to propylene glycol (more common — switch to foam).
Oral: baseline tachyarrhythmia, untreated coronary artery disease, severe renal impairment (the antihypertensive-dose pericardial-effusion risk is concentrated in this group), pregnancy, breastfeeding. Sodium retention is dose-dependent; concurrent diuretic use is sometimes needed in patients with edema tendencies. Pericardial effusion is rare at doses ≤5 mg/day — three published case reports in the LDOM-for-alopecia literature, most traceable to compounding errors (one patient was taking 1000 mg/day instead of 1 mg/day). A 51-patient echo screening at 1.25–2.5 mg/day found trivial pericardial fluid at the same rate (35%) as in controls (Randolph & Tosti 2021). Aspirin reduces SULT1A1 activity and may blunt topical response (Goren 2014).
Misconceptions
The most common misconception is that the initial 4–8 weeks of increased shedding ("dread shed") means the drug is failing. Mechanistically, minoxidil synchronises follicles by accelerating exogen — hairs already destined to shed in the coming weeks all release at once, then re-enter anagen. Patient-reported dread shed runs 5% in some LDOM cohorts, higher with topical onset. A second misconception is that the 5% foam is meaningfully less effective than 5% solution — the active ingredient and concentration are identical; only the vehicle differs (and propylene glycol's absorption-enhancing effect is partly offset by its irritation). A third is that minoxidil causes hair loss when stopped — it does not; AGA simply resumes its pre-treatment trajectory, which over 1–10 years of treatment is now a deeper deficit than at baseline. A fourth: the "magic" of LDOM as discovered by the 2022 NYT coverage — the drug had been used off-label for AGA for over a decade by then, and Sinclair's pilot was 2018.
Failure modes
Roughly 30–40% of users see clinically meaningful regrowth; another 30–40% see stabilisation; the remainder are true non-responders. Most apparent non-response traces to: (i) low SULT1A1 activity — addressable with microneedling, retinoid co-application, or switching to oral (which is sulfated systemically); (ii) inadequate adherence to twice-daily dosing over the 16–24 weeks needed for visible change; (iii) concurrent aspirin use; (iv) advanced miniaturisation (Hamilton-Norwood VI–VII, Ludwig 3) where most follicles have been lost entirely. Bayesian NMA data hints at response attenuation after 12 weeks even in responders — total regrowth at 24 weeks is lower than the linear projection from 12-week data. Switching from twice-daily to once-daily at the same concentration measurably loses density.
Practicalities
Generic 5% topical minoxidil costs ~$10–15/month for foam or ~$5–10/month for solution; annual spend $60–150 (Olsen 2002's 1 mL twice daily for a year is roughly 1.2 bottles per month). Compounded LDOM at 2.5 mg/day from a US compounding pharmacy runs $30–60/month; in Australia and parts of Europe, generic 10 mg Loniten cut into quarters or eighths is <$5/month. Telehealth services (Hims, Keeps, Happy Head, Strut) sell the topical OTC and the oral as a prescription product. The application friction — wet hair after morning dose, sticky residue from solution, twice-daily timing — is the dominant adherence barrier; oral minoxidil's single tablet is the main draw of switching to LDOM.
History
Synthesised at Upjohn in the late 1950s as a vasodilator; oral approval for severe refractory hypertension as Loniten in 1979. Hypertrichosis was reported within months of widespread oral use. Dermatologists began compounding topical preparations off-label through the early 1980s; Upjohn ran the pivotal trials and Rogaine 2% topical was FDA-approved August 17, 1988 (FDA 1988), the first hair-loss drug ever approved in the US. 5% solution followed in 1997; 5% foam in 2006; OTC for men 1996, OTC for women 2014. LDOM use for alopecia began with Sinclair's Melbourne cohort in the mid-2010s; the 2022 NYT article shifted a slow trend into a 2× prescribing surge documented in Truveta EHR data (Kolata 2022).
Stakes
AGA prevalence in men reaches ~50% by age 50 and ~80% by age 70; in women, roughly 40% by age 70. Without treatment, miniaturisation is progressive and largely irreversible past late stages — a Hamilton-Norwood V scalp at 35 is a VI at 45 and a VII at 55. The cosmetic stakes are documented in quality-of-life literature: hair loss is associated with reduced perceived attractiveness, modest self-esteem decrements, and small but measurable depression-symptom increases, particularly in women (where pattern hair loss is socially stigmatised differently than the normalised male pattern). The biological-stakes case is weaker — AGA is not a health condition in the conventional sense — but the social-mirror effect on dating, professional perception, and self-image is real.
Payoff
On responders (~40% will see clinically meaningful regrowth, another ~30% will see stabilisation), the trajectory at 3 months is reduced shedding and finer regrowth in temples and crown; at 6 months, visible density change on photographs; at 12 months, peak effect; at 5+ years, maintained density that compounds against the untreated counterfactual of accelerating miniaturisation. The catch — minoxidil only delays the trajectory while it's being used. Stopping resets within 3–6 months to the trajectory you'd have had without it; over a decade of use, that means stopping reveals a much worse scalp than baseline (Olsen 1987). Combined with a 5α-reductase inhibitor, the payoff is substantially larger and slightly more durable on cessation.
Audience
Topical 5% is FDA-approved for both men (1988) and women (1991, FPHL only — not for thinning of other patterns). LDOM is used in both sexes but female dosing is more conservative due to lower body mass and higher hypertrichosis sensitivity. Beard-enhancement use is concentrated in (i) men with patchy or sparse beards, (ii) t-AFAB individuals on testosterone-based GAHT, where the 2024 Panchaprateep trial provides the most robust data (Panchaprateep 2024). Not appropriate under 18 (no safety data). Frontal hairline in advanced AGA is the least responsive scalp region; vertex and mid-scalp are most responsive.
Out-of-scope
This entry does not cover: finasteride/dutasteride (their own entries — pair with minoxidil); ketoconazole shampoo (adjunct, low-evidence); hair transplant; PRP injections; low-level light therapy; oral spironolactone (a different mechanism, female-only). Alopecia areata, scarring alopecias, telogen effluvium, and chemotherapy-induced alopecia have separate evidence profiles and warrant separate coverage if at all.
The credibility range
Optimist case
Minoxidil is one of the best-studied dermatological interventions in existence: hundreds of RCTs, 35+ years of post-marketing surveillance, a well-mapped mechanism (SULT1A1 → KATP opening → anagen prolongation), and consistent meta-analytic support across both sexes and across formulations. The 5% topical's effect size on responders (+15 hairs/cm² over placebo at 48 weeks (Olsen 2002)) is clinically meaningful, photographically visible, and reproducible. LDOM extends the option to non-responders to topical (sulfation occurs systemically rather than requiring follicular SULT1A1) and removes the twice-daily application friction. Combined with finasteride (and microneedling adjunct), the response rate climbs to 70–90% stable-or-improved at 12 months. Beard-enhancement data is preliminary but RCT-grade. For an over-the-counter intervention with no required clinician relationship for the topical, the benefit-to-burden ratio is among the highest in cosmetic medicine.
Skeptic case
The response rate is 40% — not 90%. Half of users see no meaningful benefit, and there's no widely available pre-treatment test (the SULT1A1 assay exists but isn't standardised). The dread shed creates a real psychological barrier and adherence problem in the first 2 months. The effect is non-durable: stopping resets to baseline within 6 months, and over a decade of use, stopping reveals a substantially worse trajectory than the original baseline — patients are signing up for a lifetime commitment. Response appears to attenuate after 12 weeks in some users. Most of the trial population is 18–49; long-term data past 5 years on continuous use is observational. The most pivotal placebo-controlled trials are 24–48 weeks; sustained-efficacy claims to year 10+ are extrapolations. LDOM's risk profile is real — pericardial effusion is rare but serious, and the documented compounding-error cases are a genuine quality-control concern outside regulated pharmacies. Hypertrichosis on the face, arms, and ears affects 15–20% of LDOM users at typical doses, more in women, and is a frequent reason for discontinuation.
Author's call
Minoxidil is the highest-evidence cosmetic intervention for AGA short of hair transplant, with a well-characterised mechanism and a moderate but real effect size. Topical 5% is the default first-line — over-the-counter, cheap, low systemic risk, decades of safety. LDOM is the right move when topical adherence fails or topical response is inadequate, accepting the cardiovascular monitoring overhead and hypertrichosis risk. The honest framing is "compounding maintenance against an otherwise-progressive cosmetic deficit, not regrowth of youth": 40% of users get visible regrowth, 70% stable-or-improved, all conditional on continuing forever. The beard data is real but thin — recommendable with appropriate caveat for off-label, off-scalp use. Evidence dimension scores 5; controversy 1 (universal consensus on scalp efficacy; minor debate around oral dosing ceilings and the durability question).
Stakeholder + incentive map
- Pharmaceutical (commercial pro). Upjohn → Pfizer → Johnson & Johnson held the original Rogaine patents; off-patent since 2006 (men) and 2014 (women), so the brand-margin pressure to push topical is now low. Generic manufacturers have no marketing budget — the result is the strange situation where one of the most effective cosmetic drugs in dermatology has nearly zero broadcast-television presence.
- Telehealth (commercial pro). Hims, Keeps, Happy Head, Strut Health and dozens of compounding-pharmacy-partnered telemedicine services have built sustainable subscription businesses around minoxidil + finasteride. The 2022 NYT LDOM coverage produced documented prescribing surges and is repeatedly invoked in telehealth marketing copy.
- Dermatology (professional pro). AAD, ISHRS, and most national dermatology societies recommend topical minoxidil as first-line for AGA. The ISHRS 2022 survey reported 26% of treating physicians "always or often" prescribe oral minoxidil off-label, up from 0% in 2017.
- Sinclair lab and academic adopters (research pro). Rodney Sinclair's Melbourne group is the single most influential academic advocate for LDOM; his pilot studies underpin most contemporary dosing protocols.
- Hair-loss skeptic community. A vocal r/tressless and PerfectHairHealth contingent emphasises the durability problem and the SULT1A1 non-responder rate; they push the "test before you start" message and the microneedling adjunct.
- Regulatory. FDA approval for topical is restricted to AGA in men and FPHL in women; all oral use for alopecia is off-label. EMA, Health Canada, TGA follow similar patterns.
Population variability
- SULT1A1 activity. The single largest predictor of topical response. Low-activity genotype (AA at the SULT1A1 SNP) has ~16% response rate vs ~84% for high-activity GG (Goren 2014). LDOM bypasses follicular SULT1A1 by relying on systemic hepatic sulfation, partly explaining its utility in topical non-responders.
- Sex. FPHL response rates are comparable to male AGA at matched concentrations, but the absolute hair-count delta is smaller because the underlying loss pattern is diffuse rather than focal. Women report higher hypertrichosis rates on LDOM (facial vellus thickening at the upper lip and sideburns); doses are conventionally capped at 2.5 mg.
- Age. Most trial populations are 18–49. Older patients (60+) with longer-standing miniaturisation respond less; trials suggest the regrowth ceiling correlates with how much terminal-to-vellus conversion has already occurred.
- Region of scalp. Vertex > mid-scalp > frontal hairline for response magnitude. Receding temples in late-stage AGA may not respond meaningfully.
- Concurrent medications. Aspirin reduces SULT1A1 activity and may blunt topical response. Concurrent finasteride or dutasteride is synergistic. Concurrent diuretics may be needed in patients prone to LDOM edema.
- Facial hair. The Panchaprateep trial in transgender men on stable GAHT shows large effect sizes — confirming the androgen-receptor-density argument for facial response (Panchaprateep 2024). Cisgender men with naturally sparse beards show smaller but still significant gains in the Ingprasert 16-week trial (Ingprasert 2016).
Knowledge gaps
- Long-term LDOM cardiovascular safety beyond 5 years. Vañó-Galván's 1404-patient series follows patients for a median of ~2 years; 10-year low-dose data does not exist (Vañó-Galván 2021).
- Response attenuation after year 1. Most pivotal trials end at 48 weeks; Price's 96-week trial hinted at attenuation after week 12 within-treatment. The shape of the 5- and 10-year response curve under continuous use is observational only.
- Beard persistence on discontinuation. No controlled data. Small case series suggest terminal hairs may persist while vellus hairs regress, but this is unverified.
- Optimal LDOM dose by sex and AGA stage. Sinclair's protocols are widely followed but were derived from a small Australian cohort; optimal dose may vary with body mass, SULT1A1 status, and concomitant 5α-reductase inhibitor use.
- SULT1A1 testing. The Goren assay is published and clinically used in some centres but not standardised internationally. Whether SULT1A1 phenotyping should be standard pre-treatment is unresolved.
- Mechanism beyond KATP. The relative contribution of VEGF, PGE2, NO, and Ca2+ signalling to the clinical effect remains unclear; SUR2B-selective compounds have not yet shown superior efficacy.
Scope and brief coverage. The input description named topical and oral minoxidil for scalp and facial hair, with effects on density, regrowth, shedding cycles, side effects, and long-term cadence. All five are covered end to end: density and regrowth in evidence and payoff; shedding cycles in misconceptions (the dread shed) and payoff (weeks 2–8); side effects in contraindications; long-term cadence in protocol and payoff; facial hair in audience.
Category choice. Placed under lookmaxxing rather than medical or skin. The substance is a regulated drug, but the reader frame is cosmetic appearance management — same shelf as finasteride/dutasteride. The cardiac contraindication and prescription requirement for oral are flagged in-body.
Rating calls worth flagging.
- beauty_direct = 3, not 4. Anchor 4 reads "visible within days; consistently noticed by others." Minoxidil's visible effect lands at months 3–6, not days, and only on ~40% of users. The honest landing zone is 3.
- beauty_cumulative = 3, not 4. The long-game payoff is real — compounded against the AGA trajectory, the gap is substantial — but the score is capped by the non-responder fraction and the discontinuation reset. A "4" would imply a noticeably different aging trajectory for most users; this is true only for the responder subgroup.
- mood = 1, not 0. Borderline. The effect is indirect (mediated by appearance change) and only kicks in for responders, but the AGA / quality-of-life literature documents a real signal worth acknowledging. A 0 would over-claim that hair loss has no inner-wellbeing dimension; a 2 would over-claim that minoxidil treats it directly.
- cost_burden = 2. Generic topical solution can be as cheap as $5/month ($60/year), nudging the 1-vs-2 line. Foam and oral push the typical spend well into the $50–500 band. Defaulted to the typical case, not the cheapest possible.
- effort_burden = 2, not 3. The per-day burden is small (1–2 minutes, twice). The lifelong commitment + the wet-hair friction earn it a 2 over a 1. Pushing to 3 would conflate it with genuinely willpower-intensive routines.
- controversy = 1. Almost no serious dispute on scalp efficacy. The active debates (LDOM dose ceilings, durability past 5 years, whether SULT1A1 testing should be routine) are real but marginal.
Excluded by design.
- SULT1A1 phenotyping is mentioned but not pushed. The Goren assay is real and validated but not widely standardised; recommending it to readers as a pre-treatment step would over-claim availability.
- The dread-shed mitigation strategy of overlapping topical and oral when initiating LDOM is in the dossier but not the article — would require a longer detour than the misconceptions section warrants.
- Bayesian NMA's hint at response attenuation past week 12 is in the dossier but not surfaced in the article. The signal is suggestive, not strong enough to flag to readers.
- Eyebrow hypotrichosis, alopecia areata, telogen effluvium, scarring alopecia, and chemotherapy-induced alopecia are explicitly off-scope — different evidence profiles, different clinical handling.
Future-link candidates. finasteride and dutasteride are already in related. Worth wiring once they exist: microneedling (as adjunct), hair-transplant, ketoconazole-shampoo, pattern-hair-loss (as the condition entry minoxidil treats).
Separate-entry candidates surfaced during writing. Low-dose oral minoxidil is treated as a dose form of the same substance here, but the cardiovascular monitoring nuance, the compounding-pharmacy quality concern, and the Sinclair-protocol detail could justify a separate low-dose-oral-minoxidil entry if the catalogue ever wants drug-specificity at that resolution. Held off — would fragment the reader's view of "minoxidil" unnecessarily for now.
Honesty calls in the prose. The article leans into the 40%-respond, 30%-stabilise, 30%-nothing framing rather than the marketing-typical "works for most." This is the honest number across the literature and earns the rest of the article its credibility. Similarly, the discontinuation-reveals-underlying-loss framing in payoff and misconceptions is the harder version of the truth — softer versions would mislead.
Minoxidil
One of the most-studied cosmetic drugs ever made — FDA-approved since 1988, hundreds of trials, a mechanism worked out in detail.
Roughly $5–15 a month for the generic topical, a bit more for the oral version. Cheap per month, but it's forever.
Rub it into your scalp twice a day, every day, indefinitely. A tablet version exists if the routine wears thin.
Over 3–6 months of twice-daily use, about four in ten people see clearly thicker hair where they were thinning. Friends notice.
Keep using it for years and you hold a head of hair you'd otherwise have lost. Stop using it and the loss catches up within months.
Reversing visible hair loss takes the edge off the self-consciousness that comes with it. Real but small — and only if the drug works on you.